文献速递血栓与止血

吉普赛型血小板无力症患者针对αIIbβ3和αvβ3的免疫研究

Immunization against αIIb β3 and αv β3 in Glanzmann thrombasthenia patients carrying the French Gypsy mutation.
PubMed 文献 · J Thromb Haemost · 2020-11-18

本研究探讨携带法国吉普赛突变的血小板无力症(GT)患者针对αIIbβ3和αvβ3的免疫反应。通过改良抗原捕获试验检测HPA-1bb和HPA-1ab患者血清,发现仅HPA-1bb患者产生与HPA-1a细胞反应的同种抗体,该抗体可识别β3和/或αvβ3。提示这类患者有发生胎儿新生儿同种免疫性血小板减少症和血小板输注无效的风险。

要点

  • 吉普赛GT患者HPA-1bb基因型不表达αIIbβ3,但表达正常αvβ3且携带HPA-1b表位。
  • HPA-1bb患者可产生抗HPA-1a同种抗体,与β3和αvβ3反应。
  • 此类抗体可能引起胎儿新生儿同种免疫性血小板减少症或血小板输注无效。

核心结论

  • 不表达αIIbβ3的HPA-1bb吉普赛GT患者可产生针对HPA-1a的同种抗体,该抗体与β3及αvβ3反应。

研究设计与样本

  • 研究纳入HPA-1bb(n=5)和HPA-1ab(n=1)吉普赛GT患者,采用改良抗原捕获试验检测血清,使用血小板或稳定转染细胞,并以可溶性单体嵌合β3作为吸附剂区分抗β3和抗αvβ3反应性。

主要发现

  • 仅HPA-1bb患者产生与HPA-1a细胞反应的同种抗体。
  • 进一步分析显示HPA-1bb患者产生的抗HPA-1a同种抗体与β3和/或αvβ3反应。

临床怎么用

  • 对吉普赛GT患者,尤其HPA-1bb基因型,应警惕抗HPA-1a同种抗体形成,关注胎儿新生儿同种免疫性血小板减少症和血小板输注无效风险。

局限性

  • 研究样本量小(HPA-1bb n=5,HPA-1ab n=1),结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essentials The c.1544+1G>A mutation was identified in Gypsy Glanzmann thrombasthenia (GT) patients. Gypsy GT patients express normal αv β3 carrying HPA-1b epitopes. To demonstrate HPA-1a alloimmunization by modified antigen capture assays. Gypsy GT patients could develop anti-HPA-1a alloantibodies against β3 and αv β3 . ABSTRACT: Background Glanzmann thrombasthenia (GT) is a rare bleeding disorder caused by the absence or the dysfunction of the platelet αIIb β3 integrin. A founder mutation in the ITGA2B gene was previously identified in French Gypsy patients. Interestingly, this mutation was strongly linked to the human platelet antigen-1b (HPA-1b). The HPA-1bb Gypsy patients are at risk of isoimmunization against αIIb β3 , as this complex is not expressed at their platelet surface. Tentatively, they would, however, not have an increased risk of developing anti-HPA-1a alloantibodies by exposure of αIIb β3 on platelets from random platelet transfusions. However, the β3 chain can also associate with the αv subunit expressed at the platelet surface. Because Gypsy GT patients express normal αv β3 carrying HPA-1b epitopes, these patients might develop anti-HPA-1a alloantibodies reacting with αv β3 and/or β3 . Objectives/Patients/Methods To demonstrate this hypothesis, sera from HPA-1bb (n = 5) and HPA-1ab (n = 1) Gypsy GT patients were investigated by modified antigen capture assay using platelets or stable transfected cells. Furthermore, stable transfected cells expressing either αIIb β3 or αv β3 together with soluble monomeric chimeric β3 (as absorbent) were used to differentiate anti-β3 and anti-αv β3 reactivity. Results Only HPA-1bb patients developed alloantibodies reacting with HPA-1a cells. Further analysis showed that HPA-1bb patients developed anti-HPA-1a alloantibodies reacting with β3 and/or αv β3 . Conclusion In this study, we found that HPA-1bb patients who failed to express αIIb β3 on the platelet surface can develop alloantibodies against HPA-1a reacting with β3 as well as αv β3 . This is of particular importance as anti-HPA-1a alloantibodies might cause fetal neonatal alloimmune thrombocytopenia and/or platelet transfusion refractoriness.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Fiore M, Bayat B, Phuangtham R, et al. Immunization against αIIb β3 and αv β3 in Glanzmann thrombasthenia patients carrying the French Gypsy mutation. J Thromb Haemost. 2020. PMID: 33090654. doi:10.1111/jth.15117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。